Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Revenue	$ 799,240	$ 284,098	$ 143,140
Operating expenses:
Cost of revenue	140,561	79,649	66,849
Research and development	15,219	9,304	3,627
Selling, general and administrative	100,064	94,245	48,354
Change in estimated fair value of contingent consideration	0	0	322
Gain on sale of business	(11,249)	0	0
Gain on sale and leaseback transaction	0	(19,002)	0
Total operating expenses	244,595	164,196	119,152
Income from operations	554,645	119,902	23,988
Other income (expense):
Interest expense	(30,260)	(30,740)	(29,959)
Change in payable to related parties pursuant to a Tax Receivable Agreement	6,101	0	0
Loss on extinguishment of debt	0	(7,592)	0
Other income	279	126	118
Income (loss) before income taxes	530,765	81,696	(5,853)
Income tax expense (benefit)	61,515	2,880	(652)
Net income (loss)	469,250	78,816	(5,201)
Net income (loss) attributable to non-controlling interests	287,213	(10,156)	(731)
Net income (loss) attributable to Maravai LifeSciences Holdings, Inc.	$ 182,037	$ 88,972	$ (4,470)
Net income (loss) per Class A common share/unit attributable to Maravai LifeSciences Holdings, Inc.:
Basic (in usd per share)	$ 1.59	$ 7.43	$ (0.03)
Diluted (in usd per share)	$ 1.56	$ 2.36	$ (0.03)
Weighted average number of Class A common shares/units outstanding:
Basic (in shares)	114,791,000	10,351,000	253,917,000
Diluted (in shares)	257,803,000	28,908,000	253,917,000